E-cadherin, a cell-cell adhesion glycoprotein, is frequently downregulated with tumorigenic progression. The extracellular domain of E-cadherin is cleaved by proteases to generate a soluble ectodomain fragment, termed sEcad, which is elevated in the urine or serum of cancer patients. In this study, we explored the functional role of sEcad in the progression of skin squamous cell carcinomas (SCCs). We found that full-length E-cadherin expression was decreased and sEcad increased in human clinical tumor samples as well as in ultraviolet (UV)-induced SCCs in mice. Interestingly, sEcad associated with members of the human epidermal growth factor receptor (HER) and insulin-like growth factor-1 (IGF-1R) family of receptors in human and UV-induced mouse tumors. Moreover, in both E-cadherin-positive (E-cadherin þ ) and -negative (E-cadherin À ) cells in vitro, sEcad activated downstream mitogen-activated protein (MAP) kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling and enhanced tumor growth, motility and invasion, the latter via activation of matrix metalloproteinase-2 (MMP-2) and MMP-9. To this end, HER, PI3K or MEK inhibitors suppressed sEcad's tumorigenic effects, including proliferation, migration and invasion. Taken together, our data suggest that sEcad contributes to skin carcinogenesis via association with the HER/IGF-1R-family of receptors and subsequent activation of the MAPK and PI3K/Akt/mTOR pathways, thereby implicating sEcad as a putative therapeutic target in cutaneous SCCs.
INTRODUCTION
Full-length E-cadherin (FL-Ecad), a transmembrane glycoprotein that mediates cell-cell adhesion, contains an extracellular, a transmembrane and a highly conserved cytoplasmic domain. In most types of epithelial cancers, FL-Ecad downregulation correlates with tumor grade. 1, 2 We previously showed that FL-Ecad decreases as normal skin epithelium progresses from dysplastic lesions, to papillomas and to overt squamous cell carcinomas (SCCs) in a chronic skin photocarcinogenesis model. 3 Similarly, studies using SCC cell lines, three-dimensional human SCC tissue constructs and reports examining human skin tumors demonstrate that downregulation of FL-Ecad contributes to skin tumorigenesis. 4, 5 FL-Ecad downregulation, mediated by matrix metalloproteinases (MMPs) and members of the membrane-anchored family of metalloproteinases (ADAMs), leads to the release of an 80 kDa sEcad fragment into the tumor microenvironment. 6 sEcad is constitutively shed at low levels in normal epithelial cells, but is significantly elevated in primary prostate tumor sites and metastatic foci. 7 A correlation between heightened sEcad levels in urine, serum, and tumors and histopathological grade, metastasis recurrence and decreased survival has been described. 8, 9 In prostate and ovarian cancers, protease-induced sEcad facilitates tumor cell migration and invasion, whereas depletion of sEcad from the conditioned media reversed these effects. [10] [11] [12] Thus, it is clear that sEcad exerts pro-oncogenic effects in prostate, lung and ovarian cancers, but whether sEcad has a role in skin SCCs and the mechanisms involved, have yet to be elucidated.
The human epidermal growth factor receptor (HER) and insulinlike growth factor-1 receptor (IGF-1R) families provide strong mitogenic and pro-survival signals in skin tumors. [13] [14] [15] [16] [17] The HER family consists of four tyrosine kinase receptors, including HER1 (EGFR), HER2, HER3 and HER4. Ligand binding leads to the activation of multiple signaling pathways, including the mitogenactivated protein (MAP) kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways, which promote cancer cell proliferation, reduce apoptosis, and enhance invasiveness and angiogenesis. 18 To this end, genetic ablation or inhibitors against HER1 reduced skin tumor growth, 19, 20 whereas overexpression of HER1 ligands resulted in spontaneous skin tumor formation. 21 Transgenic K5-HER2 mice display epidermal hyperplasia and develop spontaneous skin tumors, 22 whereas overexpression of IGF-1R led to enhanced activation of IGF-1R, MAPK, PI3K and Akt signaling 17, 23 and increased skin tumor burden. 13, 17 Dual inhibition of IGF-1R and HER1 using the monoclonal antibodies A12 (IGF-1R) and Cetuximab (HER1) significantly reduced skin tumor volume and prolonged survival in a SCC orthotopic xenograft model, 24 demonstrating that HER1 and IGF-1R signaling have an important role in skin tumorigenesis.
Recent literature suggests that sEcad acts as a ligand for specific HER family members. 25, 26 Specifically, Najy et al. 25 demonstrated endogenous sEcad binding preferentially to HER2 and HER3 in the MCF-7 breast cancer cell line. In addition, exogenous sEcad or recombinant human E-cadherin/Fc chimeric protein (rhEcad/Fc) was determined to bind HER2 and HER3, enhance HER2-HER3 heterodimerization, HER3 phosphorylation and activate downstream extracellular signal-regulated kinases 1 and 2 (ERK1/2) in breast cancer cells without affecting HER2 phosphorylation. 25 In normal Madin-Darby canine kidney cells, exogenous rhEcad/Fc promoted cell survival via activation of HER1, PI3K, Akt and ERK1/2 signaling. 26 Overall, these studies suggest that sEcad may promote mitogenic, migratory and invasive properties in skin SCCs through HER receptors, enhancing MAPK and PI3K/Akt signaling and potentially inducing the activation of pro-invasive MMPs.
In this report, we used both in vivo and in vitro assays to investigate the role of sEcad in skin carcinogenesis. Here, we present evidence that FL-Ecad is downregulated concomitantly with increased shedding of sEcad during the progression of skin cancers. Furthermore, we demonstrate that sEcad associates and activates the HER/IGF-1 receptor families, via MAPK and PI3K/Akt/ mTOR signaling pathways, promoting cancer cell proliferation, migration and invasion facilitated by MMPs.
RESULTS

Downregulation of FL-Ecad corresponds with enhanced sEcad shedding
To address whether an inverse correlation between FL-Ecad and sEcad levels exists during the progression of skin cancers, we first analyzed the protein expression of FL-Ecad and sEcad in resected human skin SCCs and human and mouse cell culture systems. Western blot analysis showed a statistically significant decrease in FL-Ecad and a parallel increase in the 80 kDa sEcad fragment in SCCs versus normal skin epidermal samples from human subjects (Figure 1a) . Human SCC cell lines demonstrated a statistically significant increase in sEcad shedding versus controls, as assessed by enzyme-linked immunosorbent assay (ELISA) and immunoblot analyses (Figure 1b ). This inverse FL-Ecad/sEcad relationship was also confirmed in a chronic photocarcinogenesis skin cancer mouse model, which comprised areas of dysplasia, resected papillomas and SCCs (Figure 1c) . Interestingly, E-cadherin mRNA levels increased with ultraviolet (UV)-induced skin cancer progression ( Figure 1c ). Using an in vitro SCC skin cancer progression model, we further validated that sEcad secreted levels increased in the conditioned media of cells with progression from normal skin keratinocytes to papillomas and SCCs (Figure 1d ). sEcad enhances pro-oncogenic properties in mouse SCCs The effect of sEcad on cellular proliferation, migration and invasion was evaluated in the E-cadherin þ PAM212 and E-cadherin À CC4A cell lines. Increasing concentrations of the rmEcad/Fc resulted in a dose-dependent increase in cell proliferation in both cell lines tested (Figure 2a) . A significant increase in sEcad-induced migration of cancer cells through uncoated porous filters was also noted (Figures 2b and c) . To examine the effect of sEcad on invasion, PAM212 and CC4A cells were seeded into Transwell chambers overlaid with Matrigel to provide a three-dimensional protein-rich barrier to invasion. Cells treated with rmEcad/Fc exhibited a two to four fold increase in invasion compared with untreated controls (Figures 3a and b) . As MMPs, particularly MMP-9 and MMP-2, are key players in tumor dissemination, we evaluated the levels of pro-and active MMP-2 and MMP-9 in rmEcad/Fc-treated PAM212 cells. ELISA demonstrated a dose-dependent increase in MMP-9 secretion (Figure 3c ) and gelatin zymography demonstrated an enhanced activation of MMP-9 and MMP-2 in the conditioned media of rmEcad/Fctreated cells. To confirm that sEcad enhances invasion via MMPs, we examined the invasive potential of PAM212 cells treated with 20 mg/ml rmEcad/Fc in the presence or absence of GM6001 (Ilomastat; BIOMOL, Plymouth, PA, USA), a potent MMP inhibitor that reduces the activity of collagenases and gelatinases, including MMP-2 and MMP-9.
27 sEcad-stimulated invasion was completely blocked in the presence of GM6001 (Figure 3d ), providing further evidence for the role of sEcad-induced MMP activity in skin cancer invasion.
sEcad associates with HER/IGF-1R and activates downstream signaling To determine if sEcad exerts its effects via the HER/IGF-1R family of receptors, extracts from human SCCs were immunoprecipitated with HER1, HER2 or IGF-1Ra-specific antibodies. Immunoblotting revealed association of endogenous sEcad with HER1, HER2 and IGF-1R in human SCCs, whereas, no appreciable association of FL-Ecad with the above receptors was noted (Figure 4a) . Similarly, double immunofluorescence labeling of cryostat sectioned UV-induced tumors using an E-cadherin ectodomain-specific antibody, which recognizes both FL-Ecad and sEcad, demonstrated colocalization of E-cadherin with HER1, HER2 and IGF-1Ra (Figure 4b ). However, given the minimal levels of FL-Ecad in tumors by immunoblotting (Figure 1c) , it is most likely that the immunostaining is primarily derived from sEcad. Concomitant with increased sEcad, we observed a parallel increase in the levels of HER1, HER2 and IGF-1R phosphorylation along with activation of downstream pro-oncogenic signaling in human and UVinduced mouse SCCs compared with normal human or mouse epidermal skin samples ( Figure 4c ). Specifically, we observed heightened expression of phosphorylated MEK, as well as PI3K, Akt, mTOR and its downstream effectors 4EBP1 and p70S6K in papillomas and SCCs relative to control tissues, albeit to varying levels ( Figure 4c ). The association of sEcad with HER1, HER2 and IGF-1R was also confirmed by in vitro studies. Lysates from control and rmEcad/Fctreated PAM212 (E-cadherin þ ) were immunoprecipitated with HER1, HER2 or IGF-1R-specific antibodies and analyzed by western blotting using a His-tagged and E-cadherin extracellular domainspecific antibody for the presence of rmEcad/Fc. Our results show that sEcad co-immunoprecipitates with HER1, HER2 or IGF-1R in PAM212 cells (Figure 5a ). Next, HER/IGF-1 receptor activation was evaluated in PAM212 and CC4A cells treated with increasing concentrations of rmEcad/Fc. HER1, HER2 and IGF-1 receptor phosphorylation was notably increased by rmEcad/Fc administration in PAM212 cells (Figure 5b ). In separate experiments, the more invasive CC4A cells expressed IGF-1R and HER2 (p95), which were also dose dependently activated after rmEcad/Fc treatment ( Figure 5b ). Furthermore, rmEcad/Fc-induced MEK, ERK, PI3K and Akt phosphorylation ( Figure 5c ) and activated mTOR and its substrates p70S6K and 4EBP1 in both PAM212 and CC4A cells (Figure 5d ). Collectively, these results show that exogenous sEcad stimulates the MAPK and PI3K/Akt/mTOR axis by interacting and forming a complex with the HER and IGF-1 receptor tyrosine kinases in both E-cadherin þ and E-cadherin À cells in vitro.
HER inhibitors block sEcad-induced pro-oncogenic signaling To validate that sEcad signals via the HER family of receptors, we treated PAM212 cells with various HER inhibitors in the presence or absence of rmEcad/Fc. Canertinib, a pan-HER inhibitor, completely abrogated sEcad-induced HER1 and HER2 phosphorylation in PAM212 cells ( Figure 6a ). Lapatinib, a HER1/2 inhibitor at 5 mM, significantly downregulated the sEcad-induced phosphorylation of HER1, ERK1/2, Akt and p70S6K, but exhibited minimal changes on HER2, PI3K and 4EBP1. Gefitinib, a HER1-specific inhibitor decreased the sEcad-induced phosphorylation of HER1, ERK1/2, Akt, p70S6K and PI3K, but had only minimal effects on HER2 and 4EBP1. Canertinib, Lapatinib and Gefitinib, in the presence of sEcad, did not alter phospho-IGF-1R levels compared with their respective corresponding controls ( Figure 6a ). Next, we evaluated the effects of these inhibitors on the mitogenic, migratory and invasive capabilities in sEcad-stimulated PAM212 cells. Interestingly, all three inhibitors effectively inhibited sEcad- invasion with a less pronounced inhibition of proliferation. These results provide evidence that sEcad acts via the PI3K and MEK pathways and its substrates Akt/mTOR and ERK1/2 to facilitate pro-oncogenic properties in skin cancer cells.
DISCUSSION
Downregulation of membrane-bound E-cadherin is well known to have a pivotal role in the maintenance of cell-cell adhesion of epithelial cells, suppress cellular transformation and negatively regulate neoplastic growth in lung, colon and mammary tumors. [28] [29] [30] [31] This downregulation may be at the level of gene transcription, mRNA translation or as a result of protein posttranslational processing.
In skin carcinogenesis, we previously demonstrated that FL-Ecad protein levels significantly decrease during the progression of UV-induced skin SCCs through prostaglandin E 2 -induced internalization and degradation via the lysosome and proteasome pathways. 3 Proteolytic cleavage of transmembrane proteins, also termed ectodomain shedding, is an additional post-translational process that reduces membrane protein levels, and in some cases 6 cells. Protein loading was normalized by probing with b-actin (Santa Cruz Biotechnology) or anti-G3PDH (1:10 000, Ambion) antibodies. Band intensity was quantified using NIH Scion Image and normalized to G3PDH or b-actin. All error bars, ± s.e.m. All quantitative data were generated from a minimum of three replicates.
sEcad-induced oncogenesis via RTK interactions SM Brouxhon et al releases soluble ectodomain fragments into the extracellular milieu. Our current study demonstrates a novel inverse correlation between FL-Ecad and sEcad protein levels from normal tissues to UV-induced tumors, concomitant with increasing E-cadherin transcript levels, suggesting that ectodomain shedding contributes to FL-Ecad downregulation. This mechanism may also explain the paradox of increased levels of sEcad and low levels of membrane FL-Ecad in most cancers. Intriguingly, reports have shown that FL-Ecad is found in lymph nodes containing metastatic foci and expressed in bone, liver and other metastatic lesions when proteases are abundant. [30] [31] [32] Independently, others report enhanced sEcad expression in liver, brain and lung metastatic tissues from prostate cancer patients. 7 Yang et al. 33 demonstrated that primary gastric tumors, metastatic lymph nodes and peritoneal lavage fluid all contained E-cadherin mRNA, albeit at lower levels in primary tumors. 33 These reports, and our current data, suggest that FL-Ecad is being synthesized and subsequently downregulated via posttranslational processing, which may include shedding and/or internalization and degradation. Our data further demonstrate that sEcad has the ability to induce skin tumor cell proliferation and migration. This sEcadinduced mitogenic effect was also demonstrated by Najy et al. 25 in the SKBR3 breast cancer cell line. 25 The migratory characteristics are in concordance with studies in breast, ovarian and prostate cancer cell lines showing that recombinant sEcad chimeric protein enhances migration, whereas immunodepletion of sEcad from the conditioned media reversed these effects. 8, [10] [11] [12] Besides regulating proliferation and migration, we also found that sEcad influences SCC invasion via enhancing secretion and activation of pro-invasive MMP-2 and MMP-9, and confirmed that this invasive property was dependent on MMPs by using the MMP inhibitor GM6001. This is consistent with a previous report demonstrating enhanced sEcad-induced MT1-MMP, MMP-2 and MMP-9 secretion in transformed lung cancer cells.
11
Several observations demonstrate that increased receptor tyrosine kinase activity and downregulation of FL-Ecad function are associated with human breast and skin tumor progression. 34, 35 Specifically, FL-Ecad mediated cell-cell aggregation was inhibited by HER1/EGFR treatment, whereas inactivation of HER1/EGFR promoted E-cadherin-dependent adhesion. 35 Similarly, overexpression of FL-Ecad downregulated HER1 and reversed the invasive phenotype of human papillomavirustransfected keratinocytes. 36 Here, our data demonstrate a previously unrecognized interaction of sEcad, but minimal association of FL-Ecad, with HER1/HER2 and IGF-1R in human SCC specimens in vivo. We further demonstrate colocalization of E-cadherin with these receptors in UV-induced mouse SCCs. As membrane-bound FL-Ecad is minimally expressed in these UVinduced tumors, and we used an E-cadherin ectodomain-specific antibody that recognizes both FL-Ecad and sEcad, it is likely that the immunostaining seen on the UV-induced SCC sections is primarily from the shed ectodomain sEcad fragment. Moreover, in the human and UV-induced mouse tumors in which sEcad expression was amplified, we simultaneously found a parallel increase in HER1, HER2 and IGF-1R activation and this correlated with enhanced MAPK and PI3K/Akt/mTOR signaling. To confirm that sEcad interacts with the HER and IGF-1R, and induce their activation, we exogenously treated skin cancer cells with His-tagged recombinant sEcad. To the best of our knowledge, this is the first report to demonstrate that exogenous sEcad physically interacts and activates the HER and IGF-1R family of receptors in cutaneous SCCs in vitro. Indeed, we show sEcadinduced HER and IGF-1R phosphorylation resulting in activation of several intracellular signaling pathways, including the prooncogenic MAPK and PI3K/Akt pathways. We also provide novel evidence that sEcad signals via mTOR and its substrates 4EBP1 and p70S6K. Our results are in accordance with some of the work GM6001 for 1 h, and invasion though Matrigel analyzed in the presence of rmEcad/Fc (20 mg/ml) and 10 mM GM6001 for an additional 22 h. All error bars, ±s.e.m. All quantitative data were generated from a minimum of three replicates.
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by Najy et al. 25 , who showed that exogenous sEcad bound preferentially to HER2 and HER3, enhancing HER2-HER3 heterodimerization and activation of downstream ERK1/2 in breast cancer cells. 25 To validate that sEcad promotes oncogenicity via HER signaling in skin SCCs, we treated PAM212 cells exposed to sEcad with selective HER inhibitors. Our data demonstrated that sEcad signals through the HER receptors to activate downstream MAPK and PI3K/Akt/mTOR signaling. In support of this, we are the first to demonstrate that sEcad-induced HER transactivation mediates pro-oncogenic functions. Specifically, Canertinib, Lapatinib and Gefitinib inhibited sEcad-induced proliferation, migration and invasion. Interestingly, Canertinib at the same dose, did not affect sEcad-induced IGF-1R phosphorylation, suggesting that in our system, binding and activation of IGF-1R by sEcad is not via HER1/2 heterodimerization with IGF-1R, as previously shown in Trastuzumab-resistant cells by Nahta et al. 37 However, sEcadinduced cellular functions were abrogated by Canertinib, suggesting the existence of possible alternative downstream signaling pathways for IGF-1R and/or alternative functions. This will be explored in future studies.
To understand whether activation of MEK and PI3K are both necessary for sEcad-mediated cell proliferation, migration and invasion, the PI3K inhibitor (LY294002) and MEK inhibitor (PD98059) were used either alone or in combination. Both ERK1/2 and Akt/p70S6K phosphorylation were decreased after PI3K inhibition. Similarly, MEK inhibition resulted in decreased ERK1/2 phosphorylation. Interestingly, mTOR/p70S6K/4EBP1 
Po0.001 vs corresponding controls (C).
sEcad-induced oncogenesis via RTK interactions SM Brouxhon et al phosphorylation increased in the presence of the MEK inhibitor PD98059, even in the absence of rmEcad/Fc. This is not surprising, as it has become increasingly apparent that a complex network of horizontal and vertical signaling crosstalk and feedback loops exist between the MAPK axis and the mTOR axis, whereby inhibition of components of one axis results in a compensatory upregulation of the alternate pathway. 38 This may explain why Akt phosphorylation was enhanced by sEcad in the presence of the MEK inhibitor. In addition, as we have shown that sEcad can activate both HER and IGF-1R family members, it is plausible that this sEcad-induced Akt/mTOR/p70S6K/4EBP1 activation may occur via HER1-4 or IGF-1R signaling. Functionally, our data further show significant reductions in sEcad-induced PAM212 proliferation in the presence of the PI3K inhibitor LY294002, but less significant effects with MEK inhibitor PD98059. As the mTOR/p70S6K/4EBP1 signaling branch has a central role in regulating cell growth and proliferation, 39, 40 it is feasible that the enhanced sEcad-induced mTOR/p70S6-kinase/4EBP1 expression levels seen with PD98059 may mediate these effects. Furthermore, our data suggest that sEcad-induced proliferation, migration and invasion are PI3K and MEK-dependent, as irrespective of which inhibitor is utilized, these functional effects are blocked. This conclusion is supported by our results, wherein the PI3K and MEK inhibitors, either alone or in combination, significantly inhibited rmEcad-induced activation of MMP-2 and MMP-9.
In addition, in this study we provide novel findings that these sEcad-induced pro-oncogenic effects were evident in both E-cadherin þ and E-cadherin À SCC cell lines. In support of our data, Najy et al. 25 showed that exogenous sEcad-stimulated HER2-HER3 heterodimerization, ERK activation and cellular proliferation in the E-cadherin À SKBR3 breast cancer cell line. 25 Moreover, it is well known that the tumor microenvironment, in vivo, is a dynamic system that consists of interactions between many cell types (stromal, endothelial and inflammatory cells, and so on), soluble factors, signaling molecules, extracellular matrix and mechanical cues. Importantly, FL-Ecad is expressed on epithelial sEcad-induced oncogenesis via RTK interactions SM Brouxhon et al cells, platelets and a variety of inflammatory cells, including leukocytes and tumor-associated macrophages. [41] [42] [43] [44] As the tumor microenvironment contains an abundance of proteinases (MMPs, ADAM, and so on), and is enriched with inflammatory cells and possibly platelets with metastatic spread, it is tempting to speculate that in E-cadherin À tumors, sEcad may be derived from inflammatory or protease-mediated shedding of the E-cadherin ectodomain from these cell types. Indeed, Fong et al. 42 demonstrated that sEcad is shed from platelets 42 and Maretzky et al. 45 demonstrated that pro-inflammatory cytokines and transforming growth factor-b induced the release of sEcad in cultured keratinocytes. 45 Therefore, one cannot exclude the possibility that in the in vivo setting, enhanced pro-inflammatory cytokines, transforming growth factor-b and/or MMPs in the tumor milieu, may act in an autocrine/paracrine manner to stimulate the release of sEcad from adjacent normal epithelial cells and/or other cell types that contain FL-Ecad.
In conclusion, this study has described how FL-Ecad downregulation coincides with enhanced sEcad shedding in skin cancers, the latter, which binds HER/IGF-1R and activates downstream pro-oncogenic signaling to induce tumor cell proliferation, migration and invasion. As the HER/IGF-1R pathways are central regulators of tumor growth and survival, with dual inhibition reducing angiogenesis and cutaneous SCCs, 24 our findings may provide a strong rationale to study the clinical efficacy of antisEcad therapies for patients with primary or metastatic skin cancers.
MATERIALS AND METHODS
Cell culture, isolation and reagents
The E-cadherin þ PAM212 cells were a generous gift of Dr Yuspa (NCI, Bethesda, MD, USA), whereas the E-cadherin À CC4A cells were kindly provided by Dr Klein-Szanto (Fox Chase Cancer Center, Philadelphia, PA, USA). PAM212 cells were grown in Dulbecco's modified Eagle's medium (Lonza, Walkersville, MD, USA) with 10% fetal bovine serum, CC4A cells in minimum essential medium for suspension cultures (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and 2 mM L-glutamine and DO33, SCC12b, SCC13 cells were cultured in the presence of 3T3 feeder cells, as described previously. 46 Cell isolation and culture of primary mouse keratinocytes were performed as previously described. 3 Drug and inhibitor treatments PAM212 were seeded in six-well plates 24 h before any treatment. Cells were pre-treated for 2 h with the following inhibitors from LC Laboratories (Woburn, MA, USA): 1 mM of pan-HER (Canertinib), 5 mM of HER1/HER2 (Lapatinib) and 5 mM of HER1 (Gefitinib) inhibitors. PI3K (LY294002, 20 mM) and MEK (PD98059, 20 mM) inhibitors were purchased from EMD (Billerica, MA, USA). Recombinant mouse sEcad (rmEcad/Fc) was purchased from R&D Systems (Minneapolis, MN, USA). GM6001 was purchased from Biomol (Ann Arbor, MI, USA).
Gelatin zymography
Conditioned media from control or rmEcad/Fc-treated cells were concentrated 10-fold using Centricon devices (Millipore, Bedford, MA, USA) according to the manufacturer's instructions and applied to sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels containing gelatin (0.1% w/v). Gels were washed twice in renaturing buffer (Invitrogen, Grand Island, NY, USA) and incubated at 37 1C for 24 h in developing buffer (Invitrogen). Gels were stained with Coomassie blue and destained with methanol: acetic acid (50:10). Zymogram is representative of triplicate experiments.
Western blot analysis
Whole-cell extracts from normal human epidermal samples, human SCCs, curetted mouse epidermis, resected papillomas, resected mouse cutaneous SCCs and cells were processed for western blots, as described previously. 3 Immunoreactive bands were developed by enhanced chemiluminescence (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and visualized by autoradiography (Kodak, Rochester, NY, USA). Relative levels of total and phosphorylated proteins were determined using the following antibodies: HER1, HER2, IGF-1R, MEK1/2, ERK1/2, PI3K, Akt, mTOR, Raptor, p70S6K (Thr389), 4EBP1 (Cell Signaling Technologies, Danvers, MA, USA). Antibody to the extracellular domain of E-cadherin was obtained from Santa Cruz Biotechnology (H108). Equal protein sample loading was monitored using anti-glyceraldehyde-3-phosphate dehydrogenase (G3PDH; Ambion, Austin, TX, USA) or anti-actin (Santa Cruz Biotechnology) antibodies. Primary human SCC samples and adjacent normal epidermal skin samples were obtained from the Cooperative Human Tissue Network (CHTN; NCI) after receipt of approval from the Institutional IRB at Stony Brook University.
Immunoprecipitation
Human skin tumors and cells were homogenized and lysed in lysis buffer (20 mM Tris-HCl, pH 7.5; 137 mM NaCl; 100 mM NaF; 10% glycerol (vol/vol); 1.0% (vol/vol) Nonidet P-40; 1 mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail) (Sigma, St Louis, MO, USA). Lysates were cleared by centrifugation at 10 000 r.p.m. for 10 min at 4 1C. Supernatants were incubated with HER1/EGFR (Ab-15), HER2 (Ab-17) and IGF-1Ra (Ab4)-specific antibodies from Thermo Fisher Scientific (Rockford, IL, USA) for 4 h and protein A/G plus agarose beads (Santa Cruz Biotechnology, sc-2003) for 2 h at 4 1C. The immunocomplexes were washed three times, boiled in sample buffer and loaded on sodium dodecyl sulfate-polyacrylamide gel electrophoresis for protein analysis.
Semi-quantitative reverse transcription-PCR
Total cellular RNA from normal curetted mouse epidermis, resected papillomas and SCCs (n ¼ 2) were extracted and the level of E-cadherin mRNA was determined using a semi-quantitative reverse transcription-PCR, as previously described, 47 using the following mouse E-cadherin primers: upper primer 5 0 -GGACTACGATTATCTGAACG-3 0 , lower primer 5 0 -AACACACACACTATCCAGC-3 0 .
Immunofluorescence Paraffin-embedded UV-induced tumor sections were processed for immunofluorescence staining using E-cadherin ectodomain (Sigma, DECMA-1) and HER1, HER2 and IGF-1R-specific antibodies, as previously described. 3 Staining was detected using Alexa-488 and Alexa-594-conjugated secondary antibodies (Invitrogen) followed by Hoechst nuclear counterstaining.
ELISA assays
Conditioned media from human and mouse cells were analyzed for sEcad and MMP-9 using human and mouse E-cadherin Quantikine ELISA Kits and mouse MMP-9 ELISA kit (R&D Systems), according to the manufacturer's specifications, respectively. For measuring mouse MMP-9, serum-free medium was added to cell cultures and cells were exposed to increasing concentrations of rmEcad/Fc (R&D Systems) for 24 h. The culture media were collected and concentrated using Centrifugal Ultra Filters (Millipore, Billerica, MA, USA) and MMP-9 levels were measured by ELISA. Each experiment was performed in triplicate.
Cell proliferation assay rmEcad/Fc-stimulated PAM212 or CC4A cells, cultured in the presence or absence of inhibitors, were assayed for cell proliferation using an ELISA BrdU kit (Roche Molecular Biochemicals, Mannheim, Germany), as per the manufacturer's instructions. Results are expressed as the mean ± s.e.m., n ¼ 3.
Cell migration and invasion assays
Migration and invasion of PAM212 or CC4A cells were measured using 8.0 mm pore BD BioCoat Control Insert 24-well plates and Matrigel Invasion Chamber 24-well plates, respectively (BD Bioscience, San Jose, CA, USA). Cells were collected, washed, and 2 Â 10 5 cells were plated in 0.4% fetal bovine serum medium in the top chamber, with 0-20 mg/ml of rmEcad/Fc in the bottom chamber. After 22 h, cells on the top were removed using a cotton swab. Migrated or invaded cells on the lower surface were fixed with methanol, stained with 0.5% crystal violet, examined by bright field microscopy and photographed. In the inhibitor experiments, cells were pre-incubated with the inhibitors in the top and lower chambers for 1 or 2 h. The lower chambers were changed to the same conditions of inhibitors with rmEcad/Fc (20 mg/ml) for an additional 22 h. In some sEcad-induced oncogenesis via RTK interactions SM Brouxhon et al experiments, cells were pre-treated with 20 mM GM6001 for 1 h, then placed in the invasion chamber in the presence or absence of rmEcad/Fc together with 10 mM GM6001. Migration or invasion was quantitated by counting migrated or invaded cells in at least ten random high-power fields per insert and expressed as averages for triplicate experiments. Results are presented as fold change of the number of migrated/invaded cells to the untreated controls in triplicate experiments.
Mice and UV irradiation SKH-1 mice (Charles River Laboratories, Wilmington, MA, USA) between 8 and 14 weeks of age, and typically weighing between 20 and 30 g, were allowed free access to water and standard mouse feed. All experimental procedures were approved by the Institutional Laboratory Animal Care and Use Committee of the investigators. For the chronic photocarcinogenesis model, the dorsal skin of SKH-1 mice were exposed to 180 mJ/cm 2 UVB twice per week for 35 weeks, as previously described. 27 
Statistical analysis
Data are presented as means with standard errors (s.e.m.). Independent two-sample t-tests compare differences between two groups. A P-value below 0.05 indicated statistical significance. Statistics were analyzed with SPSS 15.0 software (SPSS Inc., Chicago, IL, USA).
